Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | OT |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | Y017208 | OT / LL |
No adverse effects reported; patient received improperly stored Proquad; This spontaneous report was received from a Nurse and refers to a 5-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 13-Jan-2025, the vaccine arrived at the facility. It was assumed that the vaccine could be refrigerated at 36 to 46 degrees Fahrenheit. On 07-Feb-2025, the patient was vaccinated with the second dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA) (PROQUAD) administered by Subcutaneous route in Left Thigh (formulation, strength, frequency, and vaccination scheme were not provided; lot # Y017208 which has been verified as a valid number, and expiration date was not reported); this vaccine was dissolved in a sterile diluent as a prophylaxis (improper storage of product in use). On an unknown date, the patient started therapy with HEO A (HAVRIX)) (Left thigh, dose 1), administered by Intramuscular route (Lot# T5727; indication, expiration date and lot # were not reported). It was unknown if a data logger was used. The patient had No adverse effects reported.
sterile diluent